1 1

Cell Signaling Institute

BPC-157: Tissue Repair & Regenerative Signaling

BPC-157: Tissue Repair & Regenerative Signaling

Home / Course / BPC-157: Tissue Repair & Regenerative Signaling

Understanding the Mechanisms Behind Body Protection Compound

BPC-157 is a 15-amino-acid sequence derived from a protein naturally found in human gastric juice. This module takes you from molecular mechanism through clinical application — covering VEGF-driven angiogenesis, fibroblast activation, nitric oxide modulation, and GI cytoprotection — and builds oral liposomal protocols grounded in evidence and structured for real patient encounters.

BPC-157 is positioned as a starter-level repair and GI peptide, appropriate for early integration into peptide practice once Foundations training is complete. Its most extensively studied domain is gastrointestinal protection — the system where oral liposomal delivery has particular mechanistic relevance.

Evidence Tier: C (Emerging) — robust preclinical data across multiple animal models; mechanistic plausibility well-established; limited published human data.

$199.00 USD
$199.00 USD
Sale Coming Soon
View full details

What You’ll Be Able To Do

  • Explain BPC-157’s mechanisms of action: angiogenesis (VEGF/VEGFR2), nitric oxide modulation, fibroblast activation (EGR-1, FAK-paxillin), and growth factor upregulation (bFGF, EGF, PDGF)
  • Identify ideal patient profiles across musculoskeletal, GI, vascular, and neuroprotective clinical domains
  • Design conservative oral liposomal starting protocols (250–500 mcg/day) with adjustment criteria, monitoring cadence, and stop rules
  • Apply BPC-157-specific inclusion/exclusion screening — including VEGF-related contraindications (active malignancy, diabetic retinopathy, anticoagulation)
  • Use evidence-tier reasoning to frame patient communication accurately and document with CSI-compliant language

Clinical Focus Areas

Musculoskeletal & Connective Tissue — Tendon, ligament, and soft tissue repair. Collagen synthesis via EGR-1 transcriptional activation. Fibroblast migration and ECM scaffold formation.

Gastrointestinal Protection — Mucosal protection, intestinal permeability, NSAID-induced injury. BPC-157’s most extensively studied domain — oral liposomal delivery places peptide directly at the clinical target.

Vascular & Endothelial Function — VEGF/VEGFR2 upregulation and collateral vessel formation. Nitric oxide modulation supporting vasodilation and endothelial barrier integrity.

Neuroprotective Signaling — Dopaminergic and serotonergic rebalancing. Gut-brain axis restoration. Preliminary preclinical evidence on nerve regeneration and CNS protection.

Who This Is For

Clinicians who have completed CSI’s Foundations course and are ready to add a repair-oriented, gut-protective peptide to their clinical toolkit. Relevant for practitioners managing musculoskeletal injury, post-surgical recovery, gastrointestinal concerns, or systemic inflammatory presentations.

Prerequisite: CSI Foundations (complimentary)

Course Details

Format: Self-paced, interactive online module via Reach 360

Time to Complete: Approximately 1 hour

Lessons: 7

Price: $199

Includes: Dosing & Protocol Desk Guide, Clinical Decision Tree, Evidence Reference Card, Competency Assessment

Frequently Asked Questions

Do I need to complete Foundations before taking this module?

Yes. Foundations covers the delivery-system science, safety architecture, compliance templates, and evidence-tier rubric that this module builds upon. With that infrastructure in place, each peptide module can focus entirely on mechanism, clinical application, and protocol design.

Is this module focused on oral liposomal or injectable BPC-157?

Protocol design and clinical integration guidance are built around oral liposomal BPC-157 — the cGMP dietary supplement pathway. The mechanistic science applies regardless of delivery route, but dosing frameworks and practice integration focus on oral liposomal use. The regulatory and compliance frameworks for compounded injectables are covered in Foundations.

What evidence supports BPC-157?

BPC-157 is classified as Evidence Tier C (Emerging): robust preclinical data across multiple animal models of tissue repair, GI protection, and angiogenesis, with strong mechanistic plausibility. Published human data is limited to early safety observations and a conference abstract on oral use as a GI adjunct. The module walks you through the full peer-reviewed evidence base with CSI-compliant framing for each reference.